DocMorris AG

ROSE

CH0042615283

Drug Retailers

Market Closed - Swiss Exchange Other stock markets 09:01:17 27/06/2024 pm IST			5-day change	1st Jan Change
53.6 ^CHF	-1.47%		-8.61%	-27.32%

19/06	DOCMORRIS : Gets a Buy rating from Jefferies	ZD
05/06	DOCMORRIS : Jefferies gives a Buy rating	ZD

ZUR ROSE GROUP : Jefferies reiterates its Buy rating

January 08, 2022 at 01:40 am IST

Analyst Alexander Thiel from Jefferies research considers the stock attractive and recommends it with a Buy rating. The target price is revised downwards from CHF 571 to CHF 515.

Latest news about DocMorris AG

DOCMORRIS : Gets a Buy rating from Jefferies	19/06	ZD
DOCMORRIS : Jefferies gives a Buy rating	05/06	ZD
DOCMORRIS : Receives a Sell rating from UBS	04/06	ZD
Warburg: Several mid-caps attractive takeover targets - and Mercedes-Benz	27/05	DP
DOCMORRIS : Warburg Research reiterates its Buy rating	27/05	ZD
Global markets live: Anglo American, Nvidia, Apple, Amazon, Tesla, Walt Disney...	23/05
DOCMORRIS : Gets a Buy rating from Baader Bank	22/05	ZD
DOCMORRIS : Gets a Sell rating from UBS	21/05	ZD
DOCMORRIS : Sell rating from UBS	16/05	ZD
DocMorris Names Successor to Outgoing CFO	08/05	MT
DocMorris Launches Tender Offer for Convertible Bonds Due 2025	06/05	MT
DOCMORRIS : Deutsche Bank remains its Buy rating	23/04	ZD
DOCMORRIS : Hauck & Aufhauser gives a Buy rating	19/04	ZD
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...	18/04
DOCMORRIS : Gets a Buy rating from Warburg Research	18/04	ZD
DOCMORRIS : Receives a Buy rating from Berenberg	18/04	ZD
DocMorris Completes CHF200 Million Convertible Bonds Offering	18/04	MT
DOCMORRIS : Gets a Buy rating from Baader Bank	17/04	ZD
DocMorris Issues CHF200 Million Convertible Bonds, Plans Tender Offer	17/04	MT
DOCMORRIS : Deutsche Bank gives a Buy rating	17/04	ZD
Swiss Stocks Flash Red as Geopolitical Risks Drag Sentiment	16/04	MT
DOCMORRIS : Warburg Research reiterates its Buy rating	16/04	ZD
DOCMORRIS : UBS reaffirms its Sell rating	16/04	ZD
DOCMORRIS : Gets a Buy rating from Jefferies	16/04	ZD
Swiss online drug delivery firm DocMorris reports slight miss in Q1 sales	16/04	RE

Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.

Sector

Drug Retailers

Calendar

20/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for DocMorris AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

53.6 CHF

Average target price

98.58 CHF

Spread / Average Target

+83.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

	1st Jan change	Capi.
DOCMORRIS AG	-27.32%	769M
JD HEALTH INTERNATIONAL INC.	-45.14%	8.72B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-25.71%	6.55B
MATSUKIYOCOCOKARA & CO.	-7.17%	6.05B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+83.84%	4.84B
NAHDI MEDICAL COMPANY	-3.80%	4.57B
YIFENG PHARMACY CHAIN CO., LTD.	-23.25%	4.27B
CLICKS GROUP LIMITED	+2.39%	4.3B
WELCIA HOLDINGS CO., LTD.	-18.67%	2.59B
REDCARE PHARMACY NV	-11.63%	2.53B

Other Drug Retailers

DocMorris AG

Equities

ROSE

CH0042615283

Drug Retailers

ZUR ROSE GROUP : Jefferies reiterates its Buy rating

Latest news about DocMorris AG

Chart DocMorris AG

Company Profile

Income Statement Evolution

Ratings for DocMorris AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Drug Retailers